The present invention relates uses of an S1P receptor modulator such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula Xfor the treatment or prevention of neo-angiogenesis associated with a demyelinating disease, e.g. multiple sclerosis.